Dr. Debu Tripathy on 10 Versus 5 Years of Adjuvant Tamoxifen

Dr. Tripathy on 10 Versus 5 Years of Aromatase InhibitorsПодробнее

Tamoxifen for Breast Cancer: 5 Years vs. 10 Years – Which is More Effective?Подробнее

2012 SABCS - Should Patients Take 10 Years of Tamoxifen After Breast Cancer?Подробнее

SABCS: Debu Tripathy Discusses Hormonal Therapy Advances in Breast CancerПодробнее

Dr. Debu Tripathy Gives an Overview of Targeted Therapies for Breast CancerПодробнее

SABCS: Debu Tripathy Examines Adjuvant Chemotherapy in Breast CancerПодробнее

Debu Tripathy on Hormonal Therapy for Breast CancerПодробнее

Dr. William Gradishar Discusses 10 Years of Adjuvant TamoxifenПодробнее

Dr. Tripathy on the Use of Tamoxifen in Hormone Receptor-Positive Breast CancersПодробнее

Meet breast medical oncologist Debu Tripathy, M.D.Подробнее

Copy of Dr. Tripathy on the Importance of Biosimilars in OncologyПодробнее

Dr. Debu Tripathy on Molecular Predictors of Outcome in Breast CancerПодробнее

Dr. Debu Tripathy Discusses The Goal of the SystHERs RegistryПодробнее

Debu Tripathy, MD, on how the APHINITY study could impact treatment of adjuvant breast cancerПодробнее

Tamoxifen Use 5 Years After Breast Cancer- Is It Effective?Подробнее

Dr. Debu Tripathy Reviews the Phase III CONFIRM TrialПодробнее

Debu Tripathy on Hormone Therapy Compliance in Patients with Breast CancerПодробнее

EXTENDED ADJUVANT HORMONAL THERAPY IN EARLY BREAST CANCERПодробнее

Dr. Tripathy on Frontline Endocrine Therapies in HR+ Breast CancerПодробнее